{"id":"NCT03952143","sponsor":"Eli Lilly and Company","briefTitle":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes","officialTitle":"A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-05-27","primaryCompletion":"2021-01-20","completion":"2021-01-20","firstPosted":"2019-05-16","resultsPosted":"2022-02-08","lastUpdate":"2022-02-08"},"enrollment":628,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"LY900014","otherNames":["Ultra-Rapid Lispro"]},{"type":"DRUG","name":"Insulin Lispro","otherNames":["LY275585","Humalog"]},{"type":"DRUG","name":"Insulin Glargine","otherNames":[]},{"type":"DRUG","name":"Insulin Degludec","otherNames":[]}],"arms":[{"label":"LY900014","type":"EXPERIMENTAL"},{"label":"Insulin Lispro","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to see if LY900014 compared to insulin lispro (Humalog), both in combination with insulin glargine or insulin degludec, is safe and effective in participants with type 2 diabetes (T2D).","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c)","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"Insulin Lispro (Humalog)","deltaMin":-0.63,"sd":0.061},{"arm":"LY900014","deltaMin":-0.56,"sd":0.046}],"pValues":[{"comp":"OG000 vs OG001","p":"0.321"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":41,"countries":["Argentina","China","Mexico"]},"refs":{"pmids":[],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/6hfa0kzMFqmoyoC8Nn6bXD"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":628},"commonTop":["Upper respiratory tract infection"]}}